Saira Khalique, Christopher J Lord, Susana Banerjee, Rachael Natrajan. Semin Cancer Biol 2020
Times Cited: 9
Times Cited: 9
Times Cited
Times Co-cited
Similarity
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
44
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
33
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
33
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
33
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji, Shogo Yamamoto, Kayo Asada, Kenbun Sone, Reiko Kurikawa, Chinami Makii,[...]. PLoS One 2015
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji, Shogo Yamamoto, Kayo Asada, Kenbun Sone, Reiko Kurikawa, Chinami Makii,[...]. PLoS One 2015
33
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
33
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan,[...]. Clin Cancer Res 2018
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan,[...]. Clin Cancer Res 2018
33
Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington. Int J Gynecol Cancer 2021
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington. Int J Gynecol Cancer 2021
33
Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Hisham Abou-Taleb, Ken Yamaguchi, Noriomi Matsumura, Ryusuke Murakami, Hidekatsu Nakai, Koichiro Higasa, Yasuaki Amano, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi,[...]. Oncotarget 2016
Hisham Abou-Taleb, Ken Yamaguchi, Noriomi Matsumura, Ryusuke Murakami, Hidekatsu Nakai, Koichiro Higasa, Yasuaki Amano, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi,[...]. Oncotarget 2016
22
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
22
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Saira Khalique, Kalnisha Naidoo, Ayoma D Attygalle, Divya Kriplani, Frances Daley, Anne Lowe, James Campbell, Thomas Jones, Michael Hubank, Kerry Fenwick,[...]. J Pathol Clin Res 2018
Saira Khalique, Kalnisha Naidoo, Ayoma D Attygalle, Divya Kriplani, Frances Daley, Anne Lowe, James Campbell, Thomas Jones, Michael Hubank, Kerry Fenwick,[...]. J Pathol Clin Res 2018
22
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
22
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
22
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
22
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
22
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
Jaime Prat. Int J Gynaecol Obstet 2014
Jaime Prat. Int J Gynaecol Obstet 2014
22
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
22
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
22
Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
22
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.
Jaime Prat. Virchows Arch 2012
Jaime Prat. Virchows Arch 2012
22
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie-Ming Shih,[...]. Cancer Discov 2015
Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie-Ming Shih,[...]. Cancer Discov 2015
22
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,[...]. Gynecol Oncol 2019
Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,[...]. Gynecol Oncol 2019
22
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke,[...]. Lancet Oncol 2016
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke,[...]. Lancet Oncol 2016
22
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Joseph J Caumanns, G Bea A Wisman, Katrien Berns, Ate G J van der Zee, Steven de Jong. Biochim Biophys Acta Rev Cancer 2018
Joseph J Caumanns, G Bea A Wisman, Katrien Berns, Ate G J van der Zee, Steven de Jong. Biochim Biophys Acta Rev Cancer 2018
22
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, Nail Fatkhutdinov, Sergey Karakashev, Timothy Nacarelli, Andrew V Kossenkov, David W Speicher, Stephanie Jean, Lin Zhang,[...]. Cell Rep 2018
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, Nail Fatkhutdinov, Sergey Karakashev, Timothy Nacarelli, Andrew V Kossenkov, David W Speicher, Stephanie Jean, Lin Zhang,[...]. Cell Rep 2018
22
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki,[...]. Cancer Cell 2019
Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki,[...]. Cancer Cell 2019
22
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Eleftherios P Samartzis, Aurelia Noske, Konstantin J Dedes, Daniel Fink, Patrick Imesch. Int J Mol Sci 2013
Eleftherios P Samartzis, Aurelia Noske, Konstantin J Dedes, Daniel Fink, Patrick Imesch. Int J Mol Sci 2013
22
Cancer-Associated Mutations in Endometriosis without Cancer.
Michael S Anglesio, Nickolas Papadopoulos, Ayse Ayhan, Tayyebeh M Nazeran, Michaël Noë, Hugo M Horlings, Amy Lum, Siân Jones, Janine Senz, Tamer Seckin,[...]. N Engl J Med 2017
Michael S Anglesio, Nickolas Papadopoulos, Ayse Ayhan, Tayyebeh M Nazeran, Michaël Noë, Hugo M Horlings, Amy Lum, Siân Jones, Janine Senz, Tamer Seckin,[...]. N Engl J Med 2017
22
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen,[...]. Oncogene 2018
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen,[...]. Oncogene 2018
22
Glutathione Metabolism: An Achilles' Heel of ARID1A-Deficient Tumors.
Chiara Gorrini, Tak W Mak. Cancer Cell 2019
Chiara Gorrini, Tak W Mak. Cancer Cell 2019
28
Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan.
H Kobayashi, K Sumimoto, N Moniwa, M Imai, K Takakura, T Kuromaki, E Morioka, K Arisawa, T Terao. Int J Gynecol Cancer 2007
H Kobayashi, K Sumimoto, N Moniwa, M Imai, K Takakura, T Kuromaki, E Morioka, K Arisawa, T Terao. Int J Gynecol Cancer 2007
22
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Chris T Williamson, Rowan Miller, Helen N Pemberton, Samuel E Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati,[...]. Nat Commun 2016
Chris T Williamson, Rowan Miller, Helen N Pemberton, Samuel E Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati,[...]. Nat Commun 2016
22
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Sarah E Taylor, Tianjiao Chu, Julia A Elvin, Robert P Edwards, Kristin K Zorn. Gynecol Oncol 2020
Sarah E Taylor, Tianjiao Chu, Julia A Elvin, Robert P Edwards, Kristin K Zorn. Gynecol Oncol 2020
25
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Bin Guan, Tian-Li Wang, Ie-Ming Shih. Cancer Res 2011
Bin Guan, Tian-Li Wang, Ie-Ming Shih. Cancer Res 2011
22
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Rowan E Miller, Rachel Brough, Ilirjana Bajrami, Chris T Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan,[...]. Mol Cancer Ther 2016
Rowan E Miller, Rachel Brough, Ilirjana Bajrami, Chris T Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan,[...]. Mol Cancer Ther 2016
22
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
22
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Sohei Yamamoto, Hitoshi Tsuda, Masashi Takano, Seiichi Tamai, Osamu Matsubara. Mod Pathol 2012
Sohei Yamamoto, Hitoshi Tsuda, Masashi Takano, Seiichi Tamai, Osamu Matsubara. Mod Pathol 2012
22
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Benjamin G Bitler, Shuai Wu, Pyoung Hwa Park, Yang Hai, Katherine M Aird, Yemin Wang, Yali Zhai, Andrew V Kossenkov, Ana Vara-Ailor, Frank J Rauscher,[...]. Nat Cell Biol 2017
Benjamin G Bitler, Shuai Wu, Pyoung Hwa Park, Yang Hai, Katherine M Aird, Yemin Wang, Yali Zhai, Andrew V Kossenkov, Ana Vara-Ailor, Frank J Rauscher,[...]. Nat Cell Biol 2017
22
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
22
Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
Shuang Ye, Jiaxin Yang, Dongyan Cao, Huimin Bai, Huifang Huang, Ming Wu, Jie Chen, Yan You, Jinghe Lang, Keng Shen. PLoS One 2015
Shuang Ye, Jiaxin Yang, Dongyan Cao, Huimin Bai, Huifang Huang, Ming Wu, Jie Chen, Yan You, Jinghe Lang, Keng Shen. PLoS One 2015
22
Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
22
Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases.
Shuang Ye, Shuling Zhou, Wei Chen, Libing Xiang, Xiaohua Wu, Huijuan Yang. Cancer Manag Res 2020
Shuang Ye, Shuling Zhou, Wei Chen, Libing Xiang, Xiaohua Wu, Huijuan Yang. Cancer Manag Res 2020
100
The target therapy of ovarian clear cell carcinoma.
Ying Jin, Yan Li, Lingya Pan. Onco Targets Ther 2014
Ying Jin, Yan Li, Lingya Pan. Onco Targets Ther 2014
22
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
22
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson. Gynecol Oncol 2018
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson. Gynecol Oncol 2018
22
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
22
Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
Boris Winterhoff, Habib Hamidi, Chen Wang, Kimberly R Kalli, Brooke L Fridley, Judy Dering, Hsiao-Wang Chen, William A Cliby, He-Jing Wang, Sean Dowdy,[...]. Gynecol Oncol 2016
Boris Winterhoff, Habib Hamidi, Chen Wang, Kimberly R Kalli, Brooke L Fridley, Judy Dering, Hsiao-Wang Chen, William A Cliby, He-Jing Wang, Sean Dowdy,[...]. Gynecol Oncol 2016
22
Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Takafumi Kuroda, Takashi Kohno. Int J Clin Oncol 2020
Takafumi Kuroda, Takashi Kohno. Int J Clin Oncol 2020
28
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.